Summary

Persistence Market Research has recently released a comprehensive report on the global Acute Myeloid Leukemia Treatment Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

• Acute Myeloid Leukemia Treatment Market Size (2025E): US$ 2.6 Bn
• Projected Market Value (2032F): US$ 5.1 Bn
• Global Market Growth Rate (CAGR 2025 to 2032): 10.0%

Acute Myeloid Leukemia Treatment Market - Report Scope:

The acute myeloid leukemia (AML) treatment market encompasses a broad range of therapeutic approaches aimed at managing and treating AML, a rapidly progressing cancer of the blood and bone marrow. Treatment options include chemotherapy, targeted therapy, and immunotherapy, administered through oral or parenteral routes. The market is witnessing significant transformation due to advancements in precision medicine, enabling personalized treatment strategies based on genetic profiling. Increasing research activities, rising healthcare investments, and improved diagnostic techniques are further contributing to the expansion of this market.

Market Growth Drivers:

The growth of the global acute myeloid leukemia treatment market is primarily driven by the increasing focus on precision medicine, which enables the customization of therapies based on individual genetic mutations, thereby improving treatment outcomes. Rising incidence of leukemia globally and growing awareness regarding early diagnosis and treatment are also contributing to market expansion. Additionally, advancements in targeted therapies such as FLT3, BCL-2, and IDH inhibitors have significantly improved survival rates, encouraging adoption. Increasing investments in oncology research and the introduction of novel drugs further support market growth.

Market Restraints:

Despite promising advancements, the acute myeloid leukemia treatment market faces several challenges. High treatment costs associated with advanced therapies and targeted drugs can limit accessibility, particularly in low- and middle-income regions. Additionally, the potential side effects and toxicity associated with chemotherapy and certain targeted therapies may hinder patient compliance. Regulatory hurdles and lengthy approval processes for new drugs also pose challenges to market growth. Limited availability of skilled healthcare professionals in certain regions further restricts treatment adoption.

Market Opportunities:

The acute myeloid leukemia treatment market presents significant opportunities driven by continuous innovation in targeted and immunotherapy treatments. The growing pipeline of novel drugs and increasing clinical trials are expected to create new avenues for market expansion. Emerging markets in Asia-Pacific and Latin America offer strong growth potential due to improving healthcare infrastructure and rising investments in cancer treatment. Furthermore, advancements in biomarker identification and companion diagnostics are expected to enhance early detection and treatment personalization, opening new opportunities for market players.

Key Questions Answered in the Report:

• What are the primary factors driving the global acute myeloid leukemia treatment market's growth?
• Which regions and market segments are experiencing the highest demand for AML treatments?
• How is precision medicine influencing treatment approaches in AML?
• Who are the key players in the acute myeloid leukemia treatment market, and what strategies are they adopting to stay competitive?
• What are the emerging trends and future projections for the global acute myeloid leukemia treatment market?

Competitive Intelligence and Business Strategy:

Leading companies in the global acute myeloid leukemia treatment market are focusing on research and development, strategic collaborations, and product innovation to strengthen their market position. These players are actively investing in the development of targeted therapies and immunotherapies to improve treatment efficacy and patient outcomes. Partnerships with research institutions and healthcare providers are enabling faster clinical development and commercialization of new drugs. Expanding global presence and strengthening distribution networks are also key strategies adopted by market players to gain a competitive edge.

Companies Covered in This Report:

• Astellas Pharma Inc.
• Bristol Myers Squibb Company
• Daiichi Sankyo Company, Limited
• Jazz Pharmaceuticals, plc
• Novartis AG
• Pfizer, Inc.
• Rigel Pharmaceuticals, Inc.
• AbbVie Inc.
• Servier Laboratories

Market Segmentation

By Treatment

• Chemotherapy
• Targeted Therapy
• Immunotherapy

By Disease

• Myeloblastic Leukemia
• Myelomonocytic Leukemia
• Leukemia
• Promyelocytic Leukemia
• Others

By Route of Administration

• Parenteral
• Oral

By Region

• North America
• Europe
• East Asia
• South Asia & Oceania
• Latin America
• Middle East & Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Acute Myeloid Leukemia Treatment Market Snapshot, 2025 and 2032
1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Macro-Economic Factors
2.3.1. Global Sectorial Outlook
2.3.2. Global GDP Growth Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
3.1. Regulatory Landscape
3.2. Product Adoption Analysis
3.3. Value Chain Analysis
3.4. Key Deals and Mergers
3.5. PESTLE Analysis
3.6. Porter’s Five Force Analysis
4. Global Acute Myeloid Leukemia Treatment Market Outlook:
4.1. Key Highlights
4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Bn) Analysis and Forecast
4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
4.2.2. Market Size (US$ Bn) Analysis and Forecast, 2025-2032
4.3. Global Acute Myeloid Leukemia Treatment Market Outlook: Treatment
4.3.1. Introduction / Key Findings
4.3.2. Historical Market Size (US$ Bn) Analysis, By Treatment, 2019-2024
4.3.3. Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2025-2032
4.3.3.1. Chemotherapy
4.3.3.1.1. Antimetabolites
4.3.3.1.2. Hypomethylating Agents (HMAs)
4.3.3.1.3. Antimetabolites
4.3.3.1.4. Anthracyclines
4.3.3.1.5. Alkylating Agents
4.3.3.1.6. Others
4.3.3.2. Targeted Therapy
4.3.3.2.1. FLT3 Inhibitors
4.3.3.2.2. BCL-2 Inhibitors
4.3.3.2.3. IDH Inhibitors
4.3.3.2.4. Others
4.3.3.3. Immunotherapy
4.3.3.3.1. Monoclonal Antibodies
4.3.3.3.2. Immune Checkpoint Inhibitors
4.3.3.3.3. Others
4.3.3.4. Others
4.3.4. Market Attractiveness Analysis: Treatment
4.4. Global Acute Myeloid Leukemia Treatment Market Outlook: Disease
4.4.1. Introduction / Key Findings
4.4.2. Historical Market Size (US$ Bn) Analysis, By Disease, 2019-2024
4.4.3. Market Size (US$ Bn) Analysis and Forecast, By Disease, 2025-2032
4.4.3.1. Myeloblastic Leukemia
4.4.3.2. Myelomonocytic
4.4.3.3. Leukemia
4.4.3.4. Promyelocytic Leukemia
4.4.3.5. Others
4.4.4. Market Attractiveness Analysis: Disease
4.5. Global Acute Myeloid Leukemia Treatment Market Outlook: Route of Administration
4.5.1. Introduction / Key Findings
4.5.2. Historical Market Size (US$ Bn) Analysis, By Route of Administration, 2019-2024
4.5.3. Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
4.5.3.1. Parenteral
4.5.3.2. Oral
4.5.4. Market Attractiveness Analysis: Route of Administration
5. Global Acute Myeloid Leukemia Treatment Market Outlook: Region
5.1. Key Highlights
5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
5.3. Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
5.3.1. North America
5.3.2. Europe
5.3.3. East Asia
5.3.4. South Asia and Oceania
5.3.5. Latin America
5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region
6. North America Acute Myeloid Leukemia Treatment Market Outlook:
6.1. Key Highlights
6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
6.2.1. By Country
6.2.2. By Treatment
6.2.3. By Disease
6.2.4. By Route of Administration
6.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
6.3.1. U.S.
6.3.2. Canada
6.4. Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2025-2032
6.4.1. Chemotherapy
6.4.1.1. Antimetabolites
6.4.1.2. Hypomethylating Agents (HMAs)
6.4.1.3. Antimetabolites
6.4.1.4. Anthracyclines
6.4.1.5. Alkylating Agents
6.4.1.6. Others
6.4.2. Targeted Therapy
6.4.2.1. FLT3 Inhibitors
6.4.2.2. BCL-2 Inhibitors
6.4.2.3. IDH Inhibitors
6.4.2.4. Others
6.4.3. Immunotherapy
6.4.3.1. Monoclonal Antibodies
6.4.3.2. Immune Checkpoint Inhibitors
6.4.3.3. Others
6.4.4. Others
6.5. Market Size (US$ Bn) Analysis and Forecast, By Disease, 2025-2032
6.5.1. Myeloblastic Leukemia
6.5.2. Myelomonocytic
6.5.3. Leukemia
6.5.4. Promyelocytic Leukemia
6.5.5. Others
6.6. Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
6.6.1. Parenteral
6.6.2. Oral
6.7. Market Attractiveness Analysis
7. Europe Acute Myeloid Leukemia Treatment Market Outlook:
7.1. Key Highlights
7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
7.2.1. By Country
7.2.2. By Treatment
7.2.3. By Disease
7.2.4. By Route of Administration
7.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
7.3.1. Germany
7.3.2. France
7.3.3. U.K.
7.3.4. Italy
7.3.5. Spain
7.3.6. Russia
7.3.7. Turkey
7.3.8. Rest of Europe
7.4. Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2025-2032
7.4.1. Chemotherapy
7.4.1.1. Antimetabolites
7.4.1.2. Hypomethylating Agents (HMAs)
7.4.1.3. Antimetabolites
7.4.1.4. Anthracyclines
7.4.1.5. Alkylating Agents
7.4.1.6. Others
7.4.2. Targeted Therapy
7.4.2.1. FLT3 Inhibitors
7.4.2.2. BCL-2 Inhibitors
7.4.2.3. IDH Inhibitors
7.4.2.4. Others
7.4.3. Immunotherapy
7.4.3.1. Monoclonal Antibodies
7.4.3.2. Immune Checkpoint Inhibitors
7.4.3.3. Others
7.4.4. Others
7.5. Market Size (US$ Bn) Analysis and Forecast, By Disease, 2025-2032
7.5.1. Myeloblastic Leukemia
7.5.2. Myelomonocytic
7.5.3. Leukemia
7.5.4. Promyelocytic Leukemia
7.5.5. Others
7.6. Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
7.6.1. Parenteral
7.6.2. Oral
7.7. Market Attractiveness Analysis
8. East Asia Acute Myeloid Leukemia Treatment Market Outlook:
8.1. Key Highlights
8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
8.2.1. By Country
8.2.2. By Treatment
8.2.3. By Disease
8.2.4. By Route of Administration
8.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
8.3.1. China
8.3.2. Japan
8.3.3. South Korea
8.4. Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2025-2032
8.4.1. Chemotherapy
8.4.1.1. Antimetabolites
8.4.1.2. Hypomethylating Agents (HMAs)
8.4.1.3. Antimetabolites
8.4.1.4. Anthracyclines
8.4.1.5. Alkylating Agents
8.4.1.6. Others
8.4.2. Targeted Therapy
8.4.2.1. FLT3 Inhibitors
8.4.2.2. BCL-2 Inhibitors
8.4.2.3. IDH Inhibitors
8.4.2.4. Others
8.4.3. Immunotherapy
8.4.3.1. Monoclonal Antibodies
8.4.3.2. Immune Checkpoint Inhibitors
8.4.3.3. Others
8.4.4. Others
8.5. Market Size (US$ Bn) Analysis and Forecast, By Disease, 2025-2032
8.5.1. Myeloblastic Leukemia
8.5.2. Myelomonocytic
8.5.3. Leukemia
8.5.4. Promyelocytic Leukemia
8.5.5. Others
8.6. Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
8.6.1. Parenteral
8.6.2. Oral
8.7. Market Attractiveness Analysis
9. South Asia & Oceania Acute Myeloid Leukemia Treatment Market Outlook:
9.1. Key Highlights
9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
9.2.1. By Country
9.2.2. By Treatment
9.2.3. By Disease
9.2.4. By Route of Administration
9.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
9.3.1. India
9.3.2. Southeast Asia
9.3.3. ANZ
9.3.4. Rest of South Asia & Oceania
9.4. Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2025-2032
9.4.1. Chemotherapy
9.4.1.1. Antimetabolites
9.4.1.2. Hypomethylating Agents (HMAs)
9.4.1.3. Antimetabolites
9.4.1.4. Anthracyclines
9.4.1.5. Alkylating Agents
9.4.1.6. Others
9.4.2. Targeted Therapy
9.4.2.1. FLT3 Inhibitors
9.4.2.2. BCL-2 Inhibitors
9.4.2.3. IDH Inhibitors
9.4.2.4. Others
9.4.3. Immunotherapy
9.4.3.1. Monoclonal Antibodies
9.4.3.2. Immune Checkpoint Inhibitors
9.4.3.3. Others
9.4.4. Others
9.5. Market Size (US$ Bn) Analysis and Forecast, By Disease, 2025-2032
9.5.1. Myeloblastic Leukemia
9.5.2. Myelomonocytic
9.5.3. Leukemia
9.5.4. Promyelocytic Leukemia
9.5.5. Others
9.6. Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
9.6.1. Parenteral
9.6.2. Oral
9.7. Market Attractiveness Analysis
10. Latin America Acute Myeloid Leukemia Treatment Market Outlook:
10.1. Key Highlights
10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
10.2.1. By Country
10.2.2. By Treatment
10.2.3. By Disease
10.2.4. By Route of Administration
10.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
10.3.1. Brazil
10.3.2. Mexico
10.3.3. Rest of Latin America
10.4. Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2025-2032
10.4.1. Chemotherapy
10.4.1.1. Antimetabolites
10.4.1.2. Hypomethylating Agents (HMAs)
10.4.1.3. Antimetabolites
10.4.1.4. Anthracyclines
10.4.1.5. Alkylating Agents
10.4.1.6. Others
10.4.2. Targeted Therapy
10.4.2.1. FLT3 Inhibitors
10.4.2.2. BCL-2 Inhibitors
10.4.2.3. IDH Inhibitors
10.4.2.4. Others
10.4.3. Immunotherapy
10.4.3.1. Monoclonal Antibodies
10.4.3.2. Immune Checkpoint Inhibitors
10.4.3.3. Others
10.4.4. Others
10.5. Market Size (US$ Bn) Analysis and Forecast, By Disease, 2025-2032
10.5.1. Myeloblastic Leukemia
10.5.2. Myelomonocytic
10.5.3. Leukemia
10.5.4. Promyelocytic Leukemia
10.5.5. Others
10.6. Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
10.6.1. Parenteral
10.6.2. Oral
10.7. Market Attractiveness Analysis
11. Middle East & Africa Acute Myeloid Leukemia Treatment Market Outlook:
11.1. Key Highlights
11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
11.2.1. By Country
11.2.2. By Treatment
11.2.3. By Disease
11.2.4. By Route of Administration
11.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
11.3.1. GCC Countries
11.3.2. Egypt
11.3.3. South Africa
11.3.4. Northern Africa
11.3.5. Rest of Middle East & Africa
11.4. Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2025-2032
11.4.1. Chemotherapy
11.4.1.1. Antimetabolites
11.4.1.2. Hypomethylating Agents (HMAs)
11.4.1.3. Antimetabolites
11.4.1.4. Anthracyclines
11.4.1.5. Alkylating Agents
11.4.1.6. Others
11.4.2. Targeted Therapy
11.4.2.1. FLT3 Inhibitors
11.4.2.2. BCL-2 Inhibitors
11.4.2.3. IDH Inhibitors
11.4.2.4. Others
11.4.3. Immunotherapy
11.4.3.1. Monoclonal Antibodies
11.4.3.2. Immune Checkpoint Inhibitors
11.4.3.3. Others
11.4.4. Others
11.5. Market Size (US$ Bn) Analysis and Forecast, By Disease, 2025-2032
11.5.1. Myeloblastic Leukemia
11.5.2. Myelomonocytic
11.5.3. Leukemia
11.5.4. Promyelocytic Leukemia
11.5.5. Others
11.6. Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
11.6.1. Parenteral
11.6.2. Oral
11.7. Market Attractiveness Analysis
12. Competition Landscape
12.1. Market Share Analysis, 2024
12.2. Market Structure
12.2.1. Competition Intensity Mapping By Market
12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
12.3.1. Astellas Pharma Inc.
12.3.1.1. Overview
12.3.1.2. Segments and Products
12.3.1.3. Key Financials
12.3.1.4. Market Developments
12.3.1.5. Market Strategy
12.3.2. Bristol Myers Squibb Company
12.3.3. Daiichi Sankyo Company, Limited
12.3.4. Jazz Pharmaceuticals, plc
12.3.5. Novartis AG
12.3.6. Pfizer, Inc.
12.3.7. Rigel Pharmaceuticals, Inc.
12.3.8. AbbVie Inc.
12.3.9. Servier Laboratories
13. Appendix
13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations